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Systems biology studies have demonstrated that different (epi)genetic and
pathophysiological alterations may be mapped onto a single tumor’s clinical phenotype
thereby revealing commonalities shared by cancers with divergent phenotypes. The
success of this approach in cancer based on analyses of traditional and emerging
body fluid-based biomarkers has given rise to the concept of liquid biopsy enabling
a non-invasive and widely accessible precision medicine approach and a significant
paradigm shift in the management of cancer. Serial liquid biopsies offer clues about the
evolution of cancer in individual patients across disease stages enabling the application
of individualized genetically and biologically guided therapies. Moreover, liquid biopsy
is contributing to the transformation of drug research and development strategies as
well as supporting clinical practice allowing identification of subsets of patients who
may enter pathway-based targeted therapies not dictated by clinical phenotypes alone.
A similar liquid biopsy concept is emerging for Alzheimer’s disease, in which blood-
based biomarkers adaptable to each patient and stage of disease, may be used for
positive and negative patient selection to facilitate establishment of high-value drug
targets and counter-measures for drug resistance. Going beyond the “one marker,
one drug” model, integrated applications of genomics, transcriptomics, proteomics,
receptor expression and receptor cell biology and conformational status assessments
during biomarker-drug co-development may lead to a new successful era for Alzheimer’s
disease therapeutics. We argue that the time is now for implementing a liquid biopsy-
guided strategy for the development of drugs that precisely target Alzheimer’s disease
pathophysiology in individual patients.
Keywords: Alzheimer’s disease, liquid biopsy, exosomes, systems pharmacology, precision medicine
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CHALLENGES IN BIOMARKER-BASED
ALGORITHM FOR DRUG R&D
PROGRAMS
The dramatic rate of Alzheimer’s disease (AD) clinical trial
failures for putative disease-modifying therapies (DmT) calls
for a shift in Research and Development (R&D) strategies.
The drug development field needs to advance to a more
comprehensive scrutinization of AD-related pathophysiology, an
earlier detection and definition of appropriate preclinical target
subpopulations, taking interindividual biological variability into
account (Cummings, 2011; Hampel et al., 2018a).
Particularly during early disease stages, evolving
decompensating molecular pathways may be effectively
regulated (Hampel et al., 2018a,b). At specific time points during
the long preclinical stage, brain network homeostasis as well as
adaptive responses and compensatory mechanisms may still be
restorable, thus ensuring resilience and ultimately prolonging
brain health-span (Hampel et al., 2018a,b).
An agnostic hypothesis-independent biomarker-driven
classification system (the A/T/N system) has been proposed to
stratify individuals according to core AD-related pathological
and pathophysiological hallmarks (brain overaccumulation
of both amyloid-β and tau proteins aggregates, and
neurodegeneration) (Jack et al., 2016). The A/T/N system
is aligned with the established conceptual framework and is
based on much-researched and largely-validated CSF and PET
biomarkers of AD. The A/T/N system is expected to provide
consistent subject enrollment and target engagement among
different sites in AD clinical trials.
Although the ATN system provides key pathophysiological
insights, it only partially reflects the expanding spectrum
of pathomechanistic alterations occurring in AD (Hampel
et al., 2018c; Molinuevo et al., 2018). Newly identified disease
mechanisms may represent relevant therapeutic targets and an
increasing number of such innovative compounds are currently
investigated by industry-led R&D programs (Hampel et al.,
2018a; Molinuevo et al., 2018).
A growing number of candidate biomarkers, capable of
charting a wider set of age- and AD-related pathophysiological
pathways is currently available, for instance: upstream regulators
of amyloidogenic pathways and axonal sprouting such as β-site
amyloid precursor protein (APP) cleaving enzyme 1 (BACE1)
(Shen et al., 2018), TAR DNA binding protein-43 (TDP-43)
(Molinuevo et al., 2018), regulators of astrocyte- and microglia-
mediated dysfunction and neuroinflammation (such as the
human cartilage glycoprotein-39 and chitinase-like protein 1,
[YKL-40] and TREM2) (Hampel et al., 2018c; Molinuevo et al.,
2018), damage of large-caliber myelinated axons [reflected by
release of neurofilament light chain (NFL)] (Mattsson et al., 2017;
Preische et al., 2019), synaptic dysfunction (reflected by release
of synaptic proteins, such as neurogranin and alpha-synuclein)
(Kvartsberg et al., 2015; Vergallo et al., 2018).
Besides biological and pathophysiological issues, a number
of challenges remain to reach the objective of translating
these criteria into an operational biomarker-based algorithm
for drug R&D programs as well as for broad clinical
diagnostic practice.
First, there is a need to better understand the role
that established, and newly identified biomarkers may play
for distinctive contexts-of-use (COU), such as for clinical
diagnosis, preclinical risk assessment and participant selection
(O’Bryant et al., 2017).
With the global epidemic rise of AD and with the exponential
increase in the number of individuals at risk and or individuals
with preclinical disease, it is urgent to step up the development of
comprehensive blood-based biomarker panels which are widely
accessible, minimally invasive, and less time- and cost-consuming
compared with CSF and neuroimaging assessment.
The collection, processing, and storage of blood is globally
accessible from biotech and pharmaceutical industry, to academic
research, until primary health care facilities. All advantages of
blood-based biomarkers compared with CSF or PET biomarkers
are essential in clinical research studies investigating large-scale
heterogeneous populations of cognitive normal individuals at risk
of AD and when time series are part of the study design.
The roadmap to ultimately validating and qualifying blood-
based biomarkers for different COU and to set up a liquid
biopsy for AD still requires an enormous worldwide-scaled effort
for the standardization and harmonization of preanalytical and
analytical protocols.
In this regard, a professional interest area focused on Blood
Based Biomarkers (BBB-PIA), as a part of the Alzheimer’s
Association’s International Society to Advance Alzheimer’s
Research and Treatment (ISTAART) as well as the European
Union-North American Clinical Trials in Alzheimer’s Disease
Task Force (EU/US CTAD Task Force) are intensely supporting
the achievement of a field-wide consensus on the harmonization
of pre-analytic and analytic protocols in order to speed up
the analytical and clinical validation of blood-based biomarkers
(Snyder et al., 2014).
In the last 5 years, several population-based studies
demonstrated correlation between CSF and blood concentrations
of different candidate markers. Moreover, several mono- and
multi-centric studies have proven a significant predictive power
of blood-based biomarkers of brain amyloidosis and tau-related
neuronal injury using PET and/or MRI imaging as a standard of
truth (Fandos et al., 2017; Mielke et al., 2018; Nakamura et al.,
2018; Park et al., 2019).
Therefore, a blood-based matrix would help overcome the
invasive and time-consuming profile of lumbar puncture and
would display an intrinsic superiority compared with PET-
based methods that can capture only a single molecular
mechanism at a time.
Such a comprehensive blood-based biomarker matrix has
already become reality in more advanced biomedical areas
including Oncology and clinical Immunology constituting the
liquid biopsy approach (Wan et al., 2017; Heitzer et al., 2019;
Pantel and Alix-Panabieres, 2019).
The U.S. National Cancer Institute (NCI) defines liquid biopsy
(LB) as “a test done on a sample of blood to look for cancer cells
from a tumor that are circulating in the blood or for pieces of
DNA from tumor cells that are in the blood”.
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The progressive field of Oncology is increasingly benefiting
from breakthrough high-resolution biomarker technologies
generating liquid biopsy-driven patient health care algorithms
and successfully implementing anti-cancer drug R&D pipelines.
Anti-cancer clinical trials are increasingly employing the
exhaustive biological tumor profiling facilitated by liquid biopsy,
which paves the way toward a paradigmatic shift to precision
medicine and pathway-based medicine. In 2017 the U.S. Food
and Drug Administration (FDA) had accelerated the approval
of two tumor type- and site- agnostic therapy approaches,
pembrolizumab and nivolumab (Goldberg et al., 2018).
We argue that the right time to develop liquid biopsy-guided
strategies for AD drug R&D pipelines is clearly approaching.
In our model we suggest that the term liquid biopsy would
equally account for any trackable bioindicators originating in
brain tissue inflicted by the pathophysiological processes of AD.
Liquid biopsy of AD will enable an early biological stratification
of large-scale heterogeneous populations of asymptomatic
individuals at risk and patients with preclinical AD. In a future
multi-stage risk-population screening strategy, liquid biopsies
may identify individuals at higher risk for AD who may be further
investigated with more specific, cost-intensive, and invasive
methods (such as CSF or PET investigations) (Hampel et al.,
2018c; Molinuevo et al., 2018).
Several blood-based candidate biomarkers reflecting
distinct pathophysiological mechanisms of AD as well as
unbiased exploratory quantitative high-throughput “omics”
biomarker platforms are increasingly gaining momentum.
We hypothesize that Neural-Derived Exosome Protein and
MicroRNAs (miRNAs) may constitute the scaffolding of
a single standardized workflow to (I) expand the current
research criteria of AD with additional molecular biomarkers
belonging to the wider spectrum of the pathophysiological
landscape of polygenic late-onset AD, (II) expand the
unbiased A/T/N biomarker classification system to
integrate comprehensive pathophysiological blood-based
biomarker information, making real-world application of
this application more feasible, cost- and time-effective and
globally accessible.
NEURAL-DERIVED EXOSOME PROTEIN
ABNORMALITIES REVEAL TARGETS
FOR PREVENTION AND THERAPY OF
CNS DISEASES IN THE ELDERLY:
NEURAL EXOSOME PROTEIN
THERAPEUTIC TARGETS
An emerging possibility for prediction of preclinical
Alzheimer disease (AD), other neurodegenerative diseases
and cerebrovascular disease is quantification of pathogenic
proteins in plasma neural cell-derived exosomes (Mustapic
et al., 2017). We will review recent progress in neural exosome
analysis, advances in clinical applications, and examples of
exosome protein biomarker candidates that may become targets
for preventative or therapeutic approaches to CNS diseases.
Exosomes derived from any type of CNS cell may be harvested
efficiently from human plasma by initial physical precipitation
followed by immunoabsorption with antibodies that selectively
recognize a surface antigen on that CNS cell-type (Mustapic
et al., 2017). This two-step process permits separate enrichment
of exosomes secreted by neurons, astrocytes, microglia and
chondroitin sulfate proteoglycan type 4 (CSPG4) cells.
The evidence for CNS cell-origin of exosomes recovered
through this process continues to accumulate. Briefly, co-authors
in this paper and others have demonstrated many-fold higher
levels for multiple known neuronal and astrocytic markers
using Western Blot and ELISA-type analyses (Goetzl et al.,
2016; Mustapic et al., 2017); enrichment for multiple neuronal
proteins based on targeted and untargeted proteomics (Pulliam
et al., 2019) and demonstration of high-yield immunocapture
of known neuronal exosomes from the plasma matrix [see
Supplementary Material in Athauda et al. (2019)]. Efforts to
directly determine the relationship between brain pathology
and circulating exosomes in animal models and humans are
currently underway.
In steady-states of chronic CNS degeneration, the plasma
concentration of exosomes from each cell-type are unchanged
by disease and neuropathological effects are seen predominantly
in the concentrations of cargo proteins per exosome (Mustapic
et al., 2017). Variations in efficiency of neural exosome isolation
from individual plasma are determined using constitutive protein
markers present at uniform levels irrespective of disease.
Normalization of biomarker levels to the same number of
exosomes with constitutive markers [such as CD81 (Fiandaca
et al., 2015) or Alix (Pulliam et al., 2019)] delineates effects
of CNS diseases. Progress using this approach includes the
following findings:
(1) Higher levels of P-T181-tau, P-S396-tau and Aβ42
in neuronally-derived exosomes (NDEs) of patients
with AD compared to age-matched controls, that were
detected as early as 10 years before overt clinical disease
(Fiandaca et al., 2015).
(2) NDE protein abnormalities characteristic of defective
autophagy, insulin resistance, synaptic dysfunction,
and reduced protection against cellular stress in AD
(Goetzl et al., 2018a).
(3) Substantially lower intracellular levels of the Aβ peptide-
generating proteins, such as β-secretase cleaving enzyme 1
(BACE-1) γ-secretase and APP in astrocytes compared to
neurons, but much higher secreted concentrations of these
proteins in astrocyte-derived exosomes (ADEs) compared
to NDEs, with ADEs of AD patients having higher levels
compared to controls (Goetzl et al., 2016).
(4) Higher concentrations of neurotoxic complement
proteins, such as C3b, Bb and C5b-C9, and lower
levels of endogenous complement inhibitors, such as
CD59, in ADEs of AD patients compared to controls
(Goetzl et al., 2018b).
(5) Higher NDE concentrations of P-T181-tau, P-S396-tau
and Aβ42, and ADE levels of complement proteins in
subjects with mild cognitive impairment (MCI) predictive
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of conversion to AD dementia in three years with
high sensitivity.
(6) Higher endothelial cell-derived exosome (EDE)
concentrations of CNS-specific endothelial proteins
in patients with clinical cerebrovascular disease compared
to controls (Goetzl et al., 2017).
(7) Higher EDE levels of CNS-specific endothelial proteins and
cytotoxic complement proteins in asymptomatic subjects
with MRI signs of small vessels cerebrovascular disease
compared to age-matched controls having normal MRIs.
Tentative evaluation of our neural-derived exosome
biomarker data suggests potential value of some cargo proteins
as therapeutic targets (Table 1). In AD, the highest value
may be assigned to blocking astrocyte complement-mediated
neurotoxicity and to restoring growth and regenerative factors of
the small, but widespread, set of CSPG4 cells. Altering activities
of various kinases and proteases and restoring levels of excitatory
synaptic proteins may also be useful efforts, but lack of specificity
is a deterrent. In cerebrovascular disease, similar efforts to
block complement-mediated endothelial toxicity are promising.
Enhancing eNOS activity in endothelial cells by suppressing
the level of NOSTRIN and enhancing angiogenesis of collateral
vessels by increasing endothelial P-YAP-1 transcriptional activity
provide optimism.
MicroRNA–MESSENGER RNA
(miRNA–mRNA) SIGNALLING IN
ALZHEIMER’S DISEASE
MicroRNAs (miRNAs) constitute a large family of small
non-coding RNA, consisting of maximum 24 nucleotides,
that exert an inhibitory function of gene expression, by
destabilizing messenger RNAs and down-regulating the
translation process (Alexandrov et al., 2012; Zhao et al., 2016).
Consequently, miRNAs may play a key regulatory role for all
intracellular signals.
The deregulation of miRNAs turn-over is associated with the
development of a broad spectrum of diseases such as cancer,
diabetes, and several pathological brain conditions including
multiple sclerosis and sporadic AD (Alexandrov et al., 2012;
Bergman et al., 2016; Sorensen et al., 2016; Zhao et al., 2016).
Research work to date has defined a small ∼5-membered
family of NF-kB-inducible miRNAs including miRNA-9,
miRNA-34a, miRNA-125b, miRNA-146a and miRNA-155 which
have been found to be up-regulated in the extracellular and
cerebrospinal fluid contiguous to AD-affected brain regions
(Alexandrov et al., 2012; Bergman et al., 2016; Sorensen et al.,
2016; Zhao et al., 2016). These results have been found in
independent studies conducted on autopsy-confirmed AD
patients, transgenic murine models of AD (TgAD), and stressed
human brain cells derived from primary cultures. These up-
regulated miRNAs appear to slow down their mRNA targets,
providing a mechanistic explanation for several interactive
AD-related failures involving phagocytosis, synaptogenesis,
bioenergetic homeostasis, modulation of inflammatory signaling,
and amyloidogenesis (Alexandrov et al., 2012; Bergman et al.,
2016; Sorensen et al., 2016; Zhao et al., 2016). For example,
the up-regulation of both miRNA-9 and miRNA-146a in
AD has been shown to down-regulate the expression of the
innate-immune glycoprotein complement factor H (CFH),
and this stimulates runaway innate-immune and inflammatory
signalling in AD that directly impacts mitochondrial-based
energy-generating capacities (Alexandrov et al., 2012; Bergman
et al., 2016; Sorensen et al., 2016; Zhao et al., 2016).
Whether these circulating miRNAs predict highly specific
genetic-epigenetic signalling pathways involved in the
TABLE 1 | Experimental therapeutic targets suggested by neural exosome protein abnormalities.
Disease Protein(s) Neural cell
source
Desired effect Estimated feasibility
as an approachable
target
AD P-tau species Neurons Suppress kinase(s) (CDK5, GSK3b, ERK2) 1
Enhance phosphatase(s)
P-S-IRS-1 Neurons Suppress kinase(s) 2
Excitatory pathway synaptic proteins Neurons Restore protein levels 2
Aβ-generating BACE-1 and γ-secretase Astrocytes Selective protease inhibitors 2
Complement (C) system [C3b, Bb, C5b-C9] Astrocytes Suppress complement activation; block C
receptors
3
Growth and regenerative factors (HGF, FGF-13, IGF-1) CSPG4 cells Restore CSPG4 proteins 3
CeVD Regulators of vascular tone and repair/regeneration
(NOSTRIN, YAP-1/P-YAP-1)
Endothelial cells Decrease NOSTRIN, increase active YAP-1 2
Complement (C) system [C3b, Bb, C5b-C9] Endothelial cells Suppress complement activation; block C
receptors
3
AD, Alzheimer disease; CeVD, cerebrovascular disease; P-S-IRS-1, serine phosphorylated type 1 insulin receptor substrate; Aβ, amyloid β peptide; BACE-1, type 1
β-secretase or type 1 β site-amyloid precursor protein cleaving enzyme; CSPG4 cell, neural cell type expressing high levels of chondroitin sulfate proteoglycan; HGF,
hepatic growth factor; FGF-13, type 13 fibroblast growth factor; IGF-1, type 1 insulin growth factor; NOSTRIN, nitric oxide synthase traffic inducer; YAP-1, type 1
Yes-associated protein; P-YAP, S127-phosphorylated YAP1. The estimated feasibility scale is: 1 = unlikely to succeed, 2 = likely to succeed if technical obstacles are
overcome, 3 = likely to be a useful approach.
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pathophysiology of sporadic AD as well as already established
fluid and neuroimaging biomarkers, will be clarified in the
coming years and may open up a therapeutic avenue to
molecular miRNA-targeted therapies.
LIQUID BIOPSY-GUIDED DRUG
DEVELOPMENT
Systems biology derived exploratory biomarkers are beginning
to bridge the historically developed separation between medical
specialties and the deconstructed disease concepts as well
as traditionally delineated drug development programs (e.g.,
within and between the different fields) (Hampel et al.,
2018a,b). Indeed, biomarker panels are untangling shared
pathways (pathophysiological and pathological commonalities)
between nosologically diverse diseases which are differently
conceptualized across different medical fields, such as Neurology,
Oncology, and clinical Immunology.
Liquid biopsies will define stage- and individual-specific
thresholds for AD pathophysiological dynamics and will
constitute the core of future disease modeling paradigms in
which different biological levels can be explored simultaneously
(Roukos, 2017; Hampel et al., 2018c). Indeed, we hypothesize that
liquid biopsy will enable to untangle the spatial and temporal
dynamics between molecular-cellular pathways and brain large-
scale brain network functional shifts, from adaptation to
resilience until systems failure and cognitive decline. Hypothesis-
independent identification and quantification of evolving risk
of detrimental mechanisms of AD will be facilitated through a
multi-purpose biomarker armamentarium (see Figure 1).
A liquid biopsy-guided stratification approach based on
upcoming clustering and other artificial intelligence methods will
create novel patient strata aggregating subjects which have similar
biomarker profiles and segregating patients which do not.
To follow, the clinical trajectories of each biological cluster
will be mapped out, hence, providing an innovative liquid
biopsy-based risk prediction matrix of AD pathophysiology in
asymptomatic at-risk individuals. Moreover, liquid biopsies may
inform a staging framework from very early pathophysiological
alterations to later preclinical and clinical manifestations. To
achieve these objectives, it is necessary to trace and model
FIGURE 1 | Liquid biopsy-guided management of Alzheimer’s disease according to a hypothetical model of spatial-temporal system-wide shifts: from adaptation to
irreversible failure. Homeostasis is ensured by adaptive responses and compensatory mechanisms scaled in time and space across multi-level system networks:
from molecular pathways, to cellular stress responses, to brain cell-to-cell and synaptic dynamics, to large-scale brain network activity, to brain-periphery
cross-talks. If a decompensatory cascade occurs, homeostasis progressively breaks down until final systems failure. Functional stage – adaptation stage – stress
responses: Metabolic and energetic reconfiguration associated with functional switch in molecular/cellular/tissue/brain systems/body system network activity.
Functional–structural stage – compensation stage – resiliency mechanisms: Structural and functional counterbalancing of one or more initial pathomechanistic
alterations. Early decompensation stage – breakdown of resiliency mechanisms: Initial and progressive loss of compensatory effect (resilience) or over sustained
compensation which may be neither protective nor homeostatic. Late decompensation stage (failure stage) – failure of resiliency mechanisms: Hypothetical point of
no-return. The colored curve line from green to red indicates a decreasing magnitude of drugs efficacy. The colored curve from green to red indicates a decreasing
magnitude of drugs efficacy. The blue rectangles indicate the different context-of-use of biomarkers according to the pathophysiological evolution.
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individual longitudinal trajectories and dynamics for each
biomarker taking into account age ranges, sex, and common
genetic variants associated with increased risk of developing AD
(Nho et al., 2013; Ferretti et al., 2018; Pimenova et al., 2018).
The catalyzing impact of systems theory, systems biology,
systems pharmacology, and precision pharmacology-oriented
drug R&D programs will ultimately support more precise future
medical strategies (Hampel et al., 2018a,b).
Systems pharmacology is a novel conceptual framework that
models traditional pharmacological parameters, derived from
pharmacodynamics and pharmacokinetics, operating under the
theoretical background of systems medicine (Geerts et al., 2015,
2018). Systems pharmacology allows modeling a drug effects
through key biological factors such as the genetic background,
sexual dimorphism and age-related pathomechanistic alterations
(Geerts et al., 2015; Roberts et al., 2016). Precision pharmacology
is a biomarker-based approach providing pathway-based
therapies through exploratory and predictive outcomes, from
initial proof-of-pharmacology to all subsequently relevant
decision-making processes (Hampel et al., 2018d).
We argue that liquid biopsy will support the proof of
pharmacology for a putative DmT which requires successful
demonstration of the capacity of a compound on several
critical levels. This means clear indication of engagement of the
intended biological target (i.e., druggability: the capacity of a
molecular target to be modulated by a small-molecule drug),
with predictable downstream alterations in pathophysiological
mechanisms, in association with clinically relevant benefits
(Geerts et al., 2015; Kozakov et al., 2015; Wu et al., 2016). For
instance, recent studies have provided proof of principle for
using protein cargo in neural-derived exosomes to demonstrate
engagement of a specific target intracellular signaling cascade
(e.g., the insulin cascade) by an experimental treatment (Eitan
et al., 2017; Athauda et al., 2019). In particular, signaling
mediators manifesting different functionality depending on their
phosphorylation state may be particularly revealing for the effects
of a drug when consistent changes are revealed in neural-derived
exosomes after treatment. Such a signal has been likened to a
“message in a bottle” (Dubal and Pleasure, 2019).
It is well established that multifactorial polygenic diseases
such as several cancers, diabetes and AD, show non-linear
pathophysiological dynamics likely due to evolutionary
conserved pathways with complex molecular cross-talks
and feedback loops and may also manifest individual differences
in drug response (Rask-Andersen et al., 2014; Mitsopoulos
et al., 2015; Deng and Nakamura, 2017; Roukos, 2017). Thus,
in cancer as well diabetes and brain diseases, the magnitude
of the improvement in clinical outcomes attained by a given
FIGURE 2 | Ideally, biomarkers should be carried through all phases of drug development and validated and qualified in agreement with regulators. The picture
shows one possible model for biomarker-drug co-development program: a regulatory scenario for a single test that would be used in conjunction with a single drug
in the clinical management of a patient. The figure highlights key events for both the diagnostic test and drug regulation with overall coordination of the regulatory
processes governing them so that the products launch together.
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small molecule may substantially change over time depending
on the stage of the disease and the individual (epi)genetic
biological background. Indeed, the likelihood of a positive
biological effect induced by specific drug on a specific target
may change over time, being related to the spatial-temporal
target druggability patterns (dynamic evolution of the ligand
binding affinity) as well as to mechanisms of drug resistance
(Rask-Andersen et al., 2014; Mitsopoulos et al., 2015; Deng
and Nakamura, 2017; Roukos, 2017). Drug-resistance refers to
the presence of gene variants that impact drug target pathways
through downstream effectors with either gain or loss of
function. Within biomarker-positive populations entering a
trial of a molecularly targeted treatment identified as druggable,
some individuals are expected to display primary or acquired
resistance (Schubbert et al., 2007; Deng and Nakamura, 2017;
Drilon et al., 2018).
Temporary patterns of target druggability may be tightly
linked to some key spatial and temporal pathophysiological
coordinates that today can be deciphered through experimental
and computational innovation integrated in the systems
medicine approach (Roberts et al., 2016; Geerts et al., 2018).
Likewise, cancer also in AD, liquid-biopsy will serve to
accomplish druggability and drug-resistance profiling, from
in silico computational prediction to in vivo biomarkers-
drug co-development programs with the approval of both
in vitro companion diagnostic device (IVD) and hopefully
effective pharmacological compounds (see Figure 2) (Jorgensen
and Hersom, 2016; Twomey et al., 2017). The feasibility
profile of liquid-biopsy (minimally invasive, cost- and time-
effective) seems to perfectly match the requirements of academic
researchers, pharma companies, and regulatory stakeholders to
successfully inform biomarker-drug co-development programs
(Nicolaides et al., 2014; Jorgensen and Hersom, 2016; Twomey
et al., 2017; Hampel et al., 2018c). This process will hopefully
translate into discovering novel targets, including some currently
considered non-druggable due to the lack of adequate surrogate
outcomes. Consequently, liquid-biopsy related biomarker-drug
co-development will improve the blueprints of clinical trials for
AD by facilitating adaptive designs.
We assume that liquid biopsy may represent a key tool of
systems pharmacology to dynamically and adaptively prioritize
potential drug targets consistent with the pathophysiological
evolution of the disease. Such focused breakthrough will support
the precise treatment of the right patient, the best druggable
target(s) at a defined time point of the disease based on a
biologically identified and classified stage.
CONCLUSION
Biomarker panels critically support objective clinical decision-
making processes in health facilities, academic research settings,
payor organizations, and pharma/biotech development programs
(O’Bryant et al., 2017; Hampel et al., 2018a).
Current efforts to re-define diagnostic criteria and bolster
programs for biomarker discovery and drug development based
on liquid-biopsy-guided disease modelling show promise to
lead us to precision medicine for AD (Nicolaides et al.,
2014; Jorgensen and Hersom, 2016; Twomey et al., 2017;
Hampel et al., 2018c).
Clinical cancer studies investigating pathway-based therapies
have shown, however, that not all biomarker-positive patients
respond to a given compound (Drilon et al., 2018). Both positive
and negative predictive biomarkers are required for detecting
and quantifying target druggability and drug resistance, guiding
the selection of patient subsets for specific treatments, and
for dynamically treating AD as its pathophysiology evolves
(Geerts et al., 2018; Gibson, 2019). To validation, qualification,
and standardization of a comprehensive liquid biopsy for AD,
blood-based biomarker panels should be subjected to rigorous
testing using large-scale observational and longitudinal studies of
cognitively intact individuals at risk of AD.
Toward this end, consequent academic-industry blood-
based biomarker- drug co-development collaboration programs
through all development stages and with strong regulatory
science consideration are required. The Interest Area focused
on Blood Based Biomarkers (BBB-PIA) - integrated in the
Alzheimer’s Association’s ISTAART, in close collaboration with
the Alzheimer Precision Medicine Initiative (APMI1) – will
continue to facilitate the stepwise identification, validation, and
standardization process of biomarker candidates (O’Bryant et al.,
2017; Hampel et al., 2018c).
These advances are required to facilitate the emerging
precision pharmacology and precision medicine paradigms in
neuroscience and neurology, as already successfully established
in other medical fields.
The emerging liquid biopsy framework is by definition not
restricted to any disease field or specialty, it is an approach
facilitated by technological and conceptual advances in the
discovery and validation of blood-based biomarkers indicative
of pathophysiological mechanisms underlying any disease.
Therefore, it becomes inherently clear that the current substantial
advances in blood-based biomarker development in AD will
subsequently lead into practical and useful liquid biopsy solutions
as part of early detection and screening as well as drug discovery
programs. These solutions are currently on the horizon, based on
strong evolving biomarker evidence.
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